Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy

Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors

(2014) Hiroshi Wakui et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling

(2014) Lei Zheng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Molecular Pathways: HER3 Targeted Therapy

(2014) K. Gala et al.   CLINICAL CANCER RESEARCH

ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

(2014) L. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

(2014) J. J. Tao et al.   Science Signaling

HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients

(2013) Soo Youn Bae et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2013) P. LoRusso et al.   CLINICAL CANCER RESEARCH

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

(2013) G. D. L. Phillips et al.   CLINICAL CANCER RESEARCH

A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer

(2013) El Mustapha Bahassi et al.   EUROPEAN JOURNAL OF CANCER

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation

(2012) S. Huang et al.   CANCER RESEARCH

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function

(2012) J. T. Garrett et al.   CLINICAL CANCER RESEARCH

HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis

(2012) Alberto Ocana et al.   JNCI-Journal of the National Cancer Institute

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

(2012) Hui-Wen Lo   Current Molecular Pharmacology

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a NovelIn VivoModel of Acquired Cetuximab Resistance

(2011) Kelly M. Quesnelle et al.   CLINICAL CANCER RESEARCH

Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer

(2011) A. Beji et al.   CLINICAL CANCER RESEARCH

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab

(2010) Deric L. Wheeler et al.   CANCER BIOLOGY & THERAPY

HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation

(2010) A. Jain et al.   CANCER RESEARCH

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

(2010) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

(2010) Fumin Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma

(2010) Chunrong Li et al.   RADIOTHERAPY AND ONCOLOGY

Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells

(2009) S. Benavente et al.   CLINICAL CANCER RESEARCH

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

(2009) C. Desbois-Mouthon et al.   CLINICAL CANCER RESEARCH

Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy

(2009) J. Veeken et al.   CURRENT CANCER DRUG TARGETS

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Nuclear EGFR contributes to acquired resistance to cetuximab

(2009) C Li et al.   ONCOGENE

Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

(2009) N. Jura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts

(2008) Jay Sarup et al.   MOLECULAR CANCER THERAPEUTICS

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells

(2008) Anthony Kong et al.   PLoS One